Background: The commonly used Fleming (FL) and Gehan phase II designs make recommendations on activity or early termination based on response rate (RR). The MN design, by incorporating early progression (PD) and RR, has been shown to perform more efficiently than FL or Gehan as assessed by appropriate early stopping for inactivity in phase II trials of cytotoxic agents [Dent S, 2001]. Because RR is a controversial endpoint for targeted agent trials, we compared the performance of MN vs. FL designs in a series of NCIC CTG phase II trials. Methods: We applied two MN stopping rules (MNA and MNB) to 15 trials evaluating single agent targeted therapies. All trials were conducted using a FL design (Ho: proportion responding p r ≤5% vs. Ha: p r ≥20%). The hypotheses were: for MNA: Ho: p r ≤5% OR proportion with PD p p ≥60% vs. Ha: p r ≥20% and p p ≤40%; for MNB: Ho: p r ≤5% AND p p ≥60% vs. Ha: p r ≥20% or p p ≤40%. The trial would stop at stage 1 by MNA if either the response OR the PD criterion for stopping were met and by MNB only if both the response AND the PD criteria for stopping were met. Sequential patient data were reviewed in each trial to tabulate a stop/go decision at the end of stage 1 based on FL, MNA and MNB and also to determine if each agent was considered active by that design at end of study. Results: FL stopped 8/15 trials: of 7 trials completing stage 2, only 2 met FL criteria for activity. The MNA rule would have stopped 12/15 trials, including 2 that the same design would have accepted as active based on the final data. FL and MNA disagreed on early stopping in 4/15 trials, all of which were eventually rejected by FL. MNB did not recommend early stopping in any trial.
